| Name | Title | Contact Details |
|---|---|---|
Vahan Tchakerian |
Senior Vice President of Sales, Americas | Profile |
At InterveXion we develop novel products for the treatment of addiction disorders. Since our founding in 2004, our team has been dedicated to providing therapeutic options for patients suffering from the debilitating effects of addiction. We occupy office and laboratory space in the BioVentures Building on the campus of the University of Arkansas for Medical Sciences (UAMS), from whom we licensed our lead technology.
Planetrx Com is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.
QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.